These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Histopathological characteristics of post kala-azar dermal leishmaniasis: a series of 88 patients. Singh A; Ramesh V; Ramam M Indian J Dermatol Venereol Leprol; 2015; 81(1):29-34. PubMed ID: 25566893 [TBL] [Abstract][Full Text] [Related]
4. A case of Post-kala-azar dermal leishmaniasis. Ono H; Ghoreishi M; Yokozeki H; Katayama I; Nishioka K J Dermatol; 1998 Feb; 25(2):118-20. PubMed ID: 9563280 [TBL] [Abstract][Full Text] [Related]
5. Post-kala-azar dermal leishmaniasis mimicking leprosy: experience with 4 patients, with some unusual features in 1. Dhar S; Kaur I; Dawn G; Sehgal S; Kumar B Lepr Rev; 1995 Sep; 66(3):250-6. PubMed ID: 7500822 [TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal. Karki P; Koirala S; Parija SC; Sethi M; Das ML Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510 [TBL] [Abstract][Full Text] [Related]
7. Post kala-azar dermal leishmaniasis: the Kenyan experience. Muigai R; Gachihi GS; Oster CN; Were JB; Nyakundi PM; Chunge CN; Kirigi G; Rashid JR East Afr Med J; 1991 Oct; 68(10):801-6. PubMed ID: 1667521 [TBL] [Abstract][Full Text] [Related]
8. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148 [TBL] [Abstract][Full Text] [Related]
9. Combination of sodium stibogluconate and rifampicin in post kala-azar dermal leishmaniasis. Sharma VK; Prasad HR; Sethuraman G; Khaitan BK Indian J Dermatol Venereol Leprol; 2007; 73(1):53-4. PubMed ID: 17314452 [No Abstract] [Full Text] [Related]
10. Post-kala-azar dermal leishmaniasis: a light and electron microscopic study of 18 cases. Mukherjee A; Ramesh V; Misra RS J Cutan Pathol; 1993 Aug; 20(4):320-5. PubMed ID: 8227608 [TBL] [Abstract][Full Text] [Related]
11. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation. Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439 [No Abstract] [Full Text] [Related]
12. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. el Hassan AM; Ghalib HW; Zijlstra EE; Eltoum IA; Satti M; Ali MS; Ali HM Trans R Soc Trop Med Hyg; 1992; 86(3):245-8. PubMed ID: 1329273 [TBL] [Abstract][Full Text] [Related]
13. Post-kala-azar dermal leishmaniasis in Nepal. Garg VK; Agrawal S; Rani S; Joshi A; Agarwalla A; Das ML; Koirala S Int J Dermatol; 2001 Mar; 40(3):179-84. PubMed ID: 11422520 [TBL] [Abstract][Full Text] [Related]
14. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Kumar D; Ramesh V; Verma S; Ramam M; Salotra P Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997 [No Abstract] [Full Text] [Related]
15. Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis. Thakur CP; Kumar K Indian J Med Res; 1990 Mar; 91():144-8. PubMed ID: 2160914 [TBL] [Abstract][Full Text] [Related]
16. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Thakur CP; Narain S; Kumar N; Hassan SM; Jha DK; Kumar A Ann Trop Med Parasitol; 1997 Sep; 91(6):611-6. PubMed ID: 9425363 [TBL] [Abstract][Full Text] [Related]
17. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873 [TBL] [Abstract][Full Text] [Related]
19. Blindness following visceral leishmaniasis: a neglected post-kala-azar complication. Khalil EA; Musa AM; Younis BM; Elfaki ME; Zijlstra EE; Elhassan AM Trop Doct; 2011 Jul; 41(3):139-40. PubMed ID: 21676981 [TBL] [Abstract][Full Text] [Related]
20. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Gilad J; Borer A; Hallel-Halevy D; Riesenberg K; Alkan M; Schlaeffer F Isr Med Assoc J; 2001 Jun; 3(6):451-2. PubMed ID: 11433642 [No Abstract] [Full Text] [Related] [Next] [New Search]